Tigecycline - how powerful is it in the fight against antibiotic-resistant bacteria?

Medicina

Volumn 46, Issue 4, 2010, Pages 240-248

  Šeputiene, Vaida ^a   Povilonis, Justas ^a   Armalyte, Julija ^a   Sužiedelis, Kȩstutis ^a   Pavilonis, Alvydas ^b   Sužiedeliene, Edita ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

^b KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

Author keywords

In vitro and in vivo activity; Mechanism of action; Resistance; Tigecycline

Indexed keywords

ANTIINFECTIVE AGENT; CL 331002; MINOCYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE;

ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG EFFECTS; FOOD AND DRUG ADMINISTRATION; GENETICS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANCE; MUTATION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCUS AUREUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MULTICENTER STUDIES AS TOPIC; MUTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STAPHYLOCOCCUS AUREUS; TETRACYCLINE RESISTANCE; TETRACYCLINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77954496087     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina46040033     Document Type: Review

References (54)

1. Madison NJ. Tygacil (tigecycline) prescribing information. Wyeth Pharmaceuticals. Available from: URL: http://www.wyeth.com/hcp/tygacil, 2007. Accessed 20 May, 2010.
2. European Medicines Agency. Available from: URL: http://www.ema.europa.eu/humandocs/Humans/EPAR/tygacil/tygacilW.htm.
3. Fraise AP. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance? J Infection 2006;53:293-300.
4. Townsend ML, Pound MW, Drew RH. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract 2006;60:1662-72.
5. Peterson LR. A review of tigecycline - the first glycylcycline. Int J Antimicrob Agents 2008;32:S215-22.
6. Testa RT, Petersen PJ, Jacobus NV, Sum PE, Lee VJ, Tally FP. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993;37:2270-7.
7. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcyline, the 9-t-butylglycylamido derivative of minocycline (GAR-396). Antimicrob Agents Chemoter 1999;43:738-44.
8. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:239-60.
9. 2+ cleavage of 16S rRNA. J Antimicrob Chem 2004;53:592-9.
10. Olson MW, Ruzin A, Feyfant E, Rush TS, O'Connel J, Bradford PA. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 2006;50:2156-66.
11. Brodersen DE, Clemons WM, Carter AP, Morgan-Warren AP, Wimberly BT, Ramakrishnan V. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the ribosomal subunit. Cell 2000;103:1143-54.
12. Mui S, Delaria K, Jurnak F. Preliminary crystallographic analysis of a complex between tetracycline and the trypsinmodified form of Escherichia coli elongation factor Tu. J Mol Biol 1990;12:445-7.
13. Aleksandrov A, Simonson, T. Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site. J Am Chem Soc 2008;130:1114-5.
14. Aleksandrov A, Simonson T. Binding of tetracyclines to elongation factor Tu, the Tet repressor and the ribosome: a molecular dynamics simulation study. Biochemistry 2008; 47:13594-603.
15. Someya Y, Yamaguchi A, Sawai T. A novel glycylcyline, 9-N, N-dimethylglycyclamido)-6 demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter. Antimicrob Agents Chemother 1995;39:247-9.
16. Connel SR, Trieber CA, Einfeld E, Dinos GP, Taylor DE, Nierhaus KH. Mechanism of Tet(O)-mediated tetracycline release. EMBO J 2003;22:945-53.
17. Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005;49:791-3.
18. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrBA multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003;47:665-9.
19. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003;47:972-8.
20. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzitcky MJ. In vitro activity of tigecycline against 6792 Gramnegative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST program, 2004). Diagn Microbiol Infect Dis 2005;52:215-7.
21. Bouchillon SK, Iredell JR, Barkham T, Lee K. Dowzicky MJ. Comparative in vitro activity of tigecyline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the tigecycline evaluation and surveillance trial (TEST). Int J Antimicrob Agents 2009;33:130-6.
22. Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009;34(2):121-30.
23. The Swedish Reference Group for Antibiotics. Tetracyclines - EUCAST clinical MIC breakpoints. Available from: URL: http://www.srga.org/eucastwt/MICTAB/MICtetracyclines.htm.
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 16th ed. Document M100-S16. Wayne, PA; CLSI; 2006.
25. Petersen PJ, Bradford PA. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother 2005;49: 3910-8.
26. Cohen Stuart J, Mouton JW, Diederen BM, Al Naiemi N, Thijsen S, Vlaminckx BJ, et al. Evaluation of Etest to determine tigecycline MICs in Enterobacter species. Antimicrob Agents Chemother 2010;54(6):2746-7.
27. Borbone S, Lupo A, Mezzatesta ML, Campanile F, Santagati M, Stefani S. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants. Int J Antimicrob Agents 2008;3:209-15.
28. Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004-2007. Diag Microbiol Infect Dis 2010;65:288-99.
29. Darabi A, Hocquet D, Dowzicky MJ. Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial. Diag Microbiol Infect Dis 2010;67:78-86.
30. Kresken M, Leitner E, Brauers J, Geiss HK, Halle E, von Eiff C, et al. Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany. Eur J Clin Microbiol Infect Dis 2009;28:83-90.
31. Ruzin A, Visalli MA, Reeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 2005;49:1017-22.
32. Kenney D, Ruzin A, McAleese F, Murphy E, Bradford PA. MarA-mediated overexpression of the AcrAB efflux pump in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 2008;61:46-53.
33. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 2000;44:2747-51.
34. Jacobus NV, McDermont LA, Ruthazer R, Snydman DR. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004;48:1034-6.
35. Bratford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in Phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicates intra-abdominal infections. Clin Infect Dis 2005;41(Suppl. 5): S315-32.
36. Nagy E, Dowzicky MJ. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis 2010;42:33-8.
37. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, et al. Tigecycline 305 cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind Phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49:4658-66.
38. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from Phase 3, randomized, double-blind trial. Int J Infect Dis 2005;9:251-61.
39. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. Tigecycline 300 cSSSI study group and the tigecycline 305 cSSSI study group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53.
40. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. Tigecycline 301 Study Group: the efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41(Suppl 5):S354-66.
41. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, et al. 309 Study Group. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008;62(Suppl 1):i29-40.
42. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, et al. 308 Study Group. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009;63:52-61.
43. Dartois N, Castaing N, Gandjini H, Cooper A. Tigecycline 313 Study Group. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J Chemother 2008;Suppl 1:28-35.
44. Werner G, Gfrörer S, Fleige C, Witte W, Klare I. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother 2008;61:1182-3.
45. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005;41 (Suppl):S333-40.
46. Kresken M, Leitner E, Brauers J, Geiss HK, Halle E, von Eiff C, et al. Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany. Eur J Clin Microbiol Infect Dis 2009;28:83-90.
47. Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb Drug Resist 2007;13:1-6.
48. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31.
49. Gordon NC, Warenham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009;63:775-80.
50. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008;62:45-55.
51. Tuckman M, Petersen PJ, Projan SJ. Mutations in the interdomain loop region resistance loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycyclcyclines. Microb Drug Resist 2000;6:277-82.
52. Hentshke M, Wolters M, Sobottka I, Rohde H, Aepfelbacher M. ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline. Antimicrob Agents Chemother 2010;54:2720-3.
53. McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Protan SJ, et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 2005;49:1865-71.
54. Moore IF, Hughes DW, Wright GD. Tigecycline is modified by the flavin-dependent monooxygenase TetX. Biochemistry 2005;44:11829-35.